Skip to main content

BioMarin Pharmaceutical Inc.

corporate_fare Company Profile

BioMarin Pharmaceutical Inc.

BMRN·NASDAQ·Life Sciences·CIK 0001048477

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company that develops medicines for people with genetically defined conditions. Founded in 1997 and based in San Rafael, California, the company has eight commercial therapies. In 2025, BioMarin achieved $3.2 billion in total revenues, with a significant contribution from VOXZOGO. The company focuses on developing and commercializing innovative therapies for patients with serious and life-threatening rare diseases and medical conditions through internal research, partnerships, and acquisitions. BioMarin conducts strategic portfolio assessments of research and development programs to evaluate scientific merit, commercial success opportunity, and potential value creation for stockholders, which may lead to the discontinuation of programs that do not meet development thresholds. In December 2025, BioMarin entered into a definitive agreement to acquire Amicus Therapeutics, Inc. for $14.50 per share in an all-cash transaction totaling approximately $4.8 billion. This acquisition is expected to add two new therapies for Fabry disease and late-onset Pompe disease to BioMarin's commercial portfolio. The transaction is expected to close in the second quarter of 2026 and will be financed through cash on hand and approximately $3.7 billion of non-convertible debt financing.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for BMRN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for BMRN spans 10-Q, 8-K, 8-K/A.

Recent high-impact activity:

  • BioMarin 10-Q Details $122.8M Q3 Loss, $4.2B Debt Load After Amicus Deal
  • BioMarin Q3 Revenue Tops $1B but FY26 EPS Guidance Cut to $2.80-$3.10
  • BioMarin Posts $122.8M Q3 Loss as Alesta Charge Hits Results
  • BioMarin Pays $70M Upfront for Second Fabry Disease Therapy
  • BioMarin Quantifies Alesta Acquisition Charges: ~$320M Pre-Tax Hit, ~$1.55 EPS Drag for 2026

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.22B
Net Income
$348.9M
Diluted EPS
$1.80
Op. Cash Flow
$827.99M
Free Cash Flow
$724.96M
Gross Profit
$2.5B
Operating Income
$409.48M
Cash & Equivalents
$1.31B
Total Debt
$597.18M
Debt / Equity
0.10×
Net Margin
10.8%
Shares Outstanding
192.3M sh
Source: 10-K · filed 2026-02-26 · accession 0001048477-26-000004

Short Interest & Short Volume

5.77 days to cover

FINRA reported short interest of 14,122,815 shares in BMRN as of the October 30, 2026 settlement, a 17.2% increase from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 47.3% of BMRN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)14,122,815 shares as of October 30, 2026
Change vs prior period▲ 17.2%
Days to cover5.77 at avg daily volume of 2,447,467
Daily short volume (FINRA facilities)47.3% of 2,421,409 shares on November 20, 2026
5-day average short volume52.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$60.02 -0.65% today
52-week range · as of 2026-11-03 $49.26 – $70.98
Market cap
$11.7B
Volume
6.1M (2.3× avg)
3-mo avg 2.7M
Live data · 2026-11-22 10:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BMRN - Latest Insights

BMRN
Nov 03, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $55.66
Real-time Price: $60.02 info
Change: +$4.36 (+8%) info
Market Cap: $11.701B info
BMRN
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $54.79
Real-time Price: $60.02 info
Change: +$5.23 (+10%) info
Market Cap: $11.701B info
BMRN
Nov 02, 2026, 4:03 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $57.44
Real-time Price: $60.02 info
Change: +$2.58 (+4%) info
Market Cap: $11.701B info
BMRN
Oct 29, 2026, 8:57 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $56.40
Real-time Price: $60.02 info
Change: +$3.62 (+6%) info
Market Cap: $11.701B info
BMRN
Oct 06, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
7
Updated Oct 6, 4:41 PM ET — BioMarin expects $283 million in pre-tax charges in Q3 from its Alesta acquisition, closed in early September.
Price at Filing: $56.22
Real-time Price: $60.02 info
Change: +$3.80 (+7%) info
Market Cap: $11.701B info
BMRN
Aug 31, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.95
Real-time Price: $60.02 info
Change: -$7.93 (-12%) info
Market Cap: $11.701B info
BMRN
Aug 31, 2026, 2:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $64.67
Real-time Price: $60.02 info
Change: -$4.65 (-7%) info
Market Cap: $11.701B info
BMRN
Aug 18, 2026, 8:39 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.06
Real-time Price: $60.02 info
Change: -$7.04 (-10%) info
Market Cap: $11.701B info
BMRN
Aug 18, 2026, 8:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $67.06
Real-time Price: $60.02 info
Change: -$7.04 (-10%) info
Market Cap: $11.701B info
BMRN
Aug 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.91
Real-time Price: $60.02 info
Change: -$3.89 (-6%) info
Market Cap: $11.701B info
BMRN
Aug 06, 2026, 4:03 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $63.63
Real-time Price: $60.02 info
Change: -$3.61 (-6%) info
Market Cap: $11.701B info
BMRN
Jul 13, 2026, 4:06 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $59.20
Real-time Price: $60.02 info
Change: +$0.820 (+1%) info
Market Cap: $11.701B info
BMRN
Jun 04, 2026, 4:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $56.47
Real-time Price: $60.02 info
Change: +$3.55 (+6%) info
Market Cap: $11.701B info
BMRN
May 20, 2026, 4:57 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $52.23
Real-time Price: $60.02 info
Change: +$7.79 (+15%) info
Market Cap: $11.701B info
BMRN
May 18, 2026, 9:09 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.05
Real-time Price: $60.02 info
Change: +$7.97 (+15%) info
Market Cap: $11.701B info
BMRN
May 05, 2026, 1:59 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $53.45
Real-time Price: $60.02 info
Change: +$6.57 (+12%) info
Market Cap: $11.701B info
BMRN
May 04, 2026, 4:18 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $55.00
Real-time Price: $60.02 info
Change: +$5.02 (+9%) info
Market Cap: $11.701B info
BMRN
Apr 27, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $53.94
Real-time Price: $60.02 info
Change: +$6.08 (+11%) info
Market Cap: $11.701B info
BMRN
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $53.94
Real-time Price: $60.02 info
Change: +$6.08 (+11%) info
Market Cap: $11.701B info
BMRN
Apr 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $53.91
Real-time Price: $60.02 info
Change: +$6.11 (+11%) info
Market Cap: $11.701B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets